1.Relationship between Prader-Willi syndrome and sleep related breathing disorders
International Journal of Pediatrics 2016;43(9):669-672
Prader-Willi syndrome( PWS) is a type of genetic disease,which is associated with low mus-cle tone,growth and development,progressive fatal obesity and sleep related respiratory disorders(SRBD). Ob-structive sleep apnea hypopnea syndrome( OSAHS) is the most common type of SRBD. The cause,influencing factors and treatment of OSAHS in patients with PWS are described in this paper. To understand the degree of OSAHS in children with PWS,the polysomnography is recommended.
2.Effect of Yiqi - Huoxue (Qi - strengthening Blood activating) Method on Hemorheological Indexes in Senile Convalescent Apoplexy and Its Sequelae
Journal of Traditional Chinese Medicine 1993;0(05):-
One hundred sixty cases were randomly divided into 2 groups, the treatment group and control group, and treated for 8 weeks by single blind administering method. Results revealed that the total effective rate (89. 5%) for clinical symptoms in the treatment group was far superior to that of control group (54. 2%). So was its effect on nervous functional defect. The total blood viscosity. plasmal comparative viscosity, platelet adhesion, thrombic elstic fingure. in vitro length of thrombus, were markedly improved (P
3.The role of PDGF/PDGFR in the regulation of platelet formation.
Mo YANG ; Ling-Ling SHU ; Yun CUI
Journal of Experimental Hematology 2011;19(5):1097-1101
Platelet-derived growth factor (PDGF), a potent chemotactic and mitogenic factor, is involved in the regulation of hematopoiesis and platelet production. Our studies demonstrate the presence of functional PDGF receptors (PDGFR) on human megakaryocytes/platelets and CD34(+) cells, and their ability to mediate a mitogenic response. PDGF promotes the ex vivo expansion of human hematopoietic stem (CD34(+)) and progenitor (CD41(+)) cells. More significantly, PDGF enhances the engraftment of human CD45(+) cells and their myeloid subsets (CD33(+), CD14(+) cells) in NOD/SCID mice. PDGF also stimulates in vitro megakaryocytopoiesis via PDGFR and/or the indirect effect on bone marrow microenvironment to produce TPO and other cytokines. It also shows a direct stimulatory effect of PDGF on c-Fos, GATA-1 and NF-E2 expressions in megakaryocytes. We speculate that these transcription factors may be involved in the signal transduction of PDGF on the regulation of megakaryocytopoiesis. PDGF also enhances platelet recovery in mouse model with radiation-induced thrombocytopenia. This radioprotective effect is likely to be mediated via PDGFR with subsequent activation of the PI3K/Akt pathway. It provides a possible explanation that blockage of PDGFR may reduce thrombopoiesis and play a role in imatinib mesylate-induced thrombocytopenia.
Animals
;
Hematopoietic Stem Cells
;
cytology
;
Humans
;
Megakaryocytes
;
cytology
;
Mice
;
Platelet-Derived Growth Factor
;
metabolism
;
Receptors, Platelet-Derived Growth Factor
;
metabolism
;
Thrombopoiesis
4. Expression of CYR61 in human lung cancer tissues and its clinical significance
Tumor 2007;27(4):286-289
Objective: To investigate the biological functions of the Cyr61 gene in human lung carcinomas. Methods: The Cyr61 expression levels in the cancerous and peri-cancerous tissues of 60 lung cancer patients were measured by real-time polymerase chain reaction (PCR). Results: The expression of Cyr61 gene was down-regulated in 80% (48/60) primary lung cancer patients compared with the matched pericancerous tissues. The result was consistent with the immunohistochemical staining. Statistical analysis revealed that the difference between expression of cancerous tissues and the matched peri-cancerous tissues was significant [(2.742 ± 4.165) vs (4.933 ± 3.349), t = -5.112, P=0.000]. Furthermore, the clinical variables including tumor grade, tumor metastasis, tumor pathological classification, smoking, and family history influenced the level of Cyr61 expression (P<0.05). Conclusion: Cyr61 may play a key role in the progression of lung carcinoma and its protein might serve as an important target for the therapeutic intervention in clinic.
5.Annexin A2 and pathogenesis of cancer: an update.
Chinese Journal of Pathology 2007;36(2):129-132
8.Systemic mastocytosis.
Jun SHI ; Cui-ling LI ; Tao XU
Chinese Journal of Pediatrics 2005;43(4):317-318
9.Effect of obstructive sleep apnea/hypopnea syndrome (OSAHS) on the cognitive function of pilots
Li CUI ; Xianrong XU ; Ling WANG
Medical Journal of Chinese People's Liberation Army 2001;0(11):-
Objective To explore the effects of obstructive sleep apnea/hypopnea syndrome (OSAHS) on the cognitive function of pilots. Methods The cognitive function of 13 pilots diagnosed as severe OSAHS and 10 healthy pilots as control was evaluated using Epworth Sleepiness Scale (ESS), Flicker Fusion Frequency Indicator, Many Reaction Time Tester, Space Place Memory Span Tester, Attention Instrument and Guard Tester. The correlation analyses were also performed between the ESS, AHI, MinSaO2% with the results of each cognitive test in the OSAHS group. Results Compared with the healthy control subjects, the scores of ESS in OSAHS group were significantly higher (P
10.Subtypes of breast cancer show different patterns of metastasis:a 10-year survival analysis of 390 patients with primary breast cancer
Shien CUI ; Bing CHU ; Feihai LING
China Oncology 2015;(10):774-779
Background and purpose:Breast cancer can be divided into several molecular subtypes according to its biomarkers. The pattern of distant metastasis has a great clinic significance but was rarely investigated. This study investigated the impact of molecular subtype of breast cancer on initial sites of metastasis..Methods:All the patients with operable invasive breast cancer diagnosed in Zhongshan People’s Hospital between 1998 and 2004 were recruited. Subtypes were defined as Luminal A, Luminal B, human epidermal growth factor receptor 2 (HER-2) enriched, and triple negative (TN) according to the expression of estrogen receptor (ER), progestogen receptor (PR) and HER-2 status. The first distant metastatic sites and the time of their appearances were recorded. Survival curves were constructed using the Ka-plan-Meier technique.Results:Among 390 eligible patients, there were 215(55.1%) with Luminal A, 43 (11.0%) with Lu-minal B, 52 (13.3%) with HER-2 enriched, and 80 (20.5%) with TN. The median follow-up time was 118 months (11-163 months). Seventy-two (18.5%) distant metastases occurred during follow-up: 37 metastases in Luminal A, 8 in Luminal B, 10 in HER-2, 17 in TN. Bone was the most common site of the first distant metastasis (39/72, 54.2%) followed by lung (25/72, 34.7%), liver (22/72, 30.6%), and brain (7/72, 9.7%). Among all the metastases, tumors of Luminal type (Luminal A 70.2%, Luminal B 50.0%) had a higher chance of bone involvement than that of HER-2 enriched (30.0%) and TN (35.3%,P=0.03). Both Luminal B (37.5%) and TN (17.6%) subtypes had a higher percentage of brain involvement than Luminal A and HER-2 enriched (P=0.01). The survival analysis showed no significant difference among the four subtypes in 9-year distant metastasis-free survival. However, distant metastasis appeared earlier in HER-2 enriched and TN breast cancer than in Luminal type.Conclusion:Organ-specific metastasis may depend on the molecular subtype of breast cancer. Bone metastasis occurs more in luminal type than in other types. Luminal B and TN types of tumors had more chance of brain metastasis than Luminal A and HER-2 enriched type of tumors.